Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Ewan C Goligher, Charlotte A Bradbury, Bryan J McVerry, Patrick R Lawler, Jeffrey S Berger, Michelle N Gong, Marc Carrier, Harmony R Reynolds, Anand Kumar, Alexis F Turgeon, Lucy Z Kornblith, Susan R Kahn, John C Marshall, Keri S Kim, Brett L Houston, Lennie P G Derde, Mary Cushman, Tobias Tritschler, Derek C Angus, Lucas C Godoy, Zoe McQuilten, Bridget-Anne Kirwan, Michael E Farkouh, Maria M Brooks, Roger J Lewis, Lindsay R Berry, Elizabeth Lorenzi, Anthony C Gordon, Tania Ahuja, Farah Al-Beidh, Djillali Annane, Yaseen M Arabi, Diptesh Aryal, Lisa Baumann Kreuziger, Abi Beane, Zahra Bhimani, Shailesh Bihari, Henny H Billett, Lindsay Bond, Marc Bonten, Frank Brunkhorst, Meredith Buxton, Adrian Buzgau, Lana A Castellucci, Sweta Chekuri, Jen-Ting Chen, Allen C Cheng, Tamta Chkhikvadze, Benjamin Coiffard, Aira Contreras, Todd W Costantini, Sophie de Brouwer, Michelle A Detry, Abhijit Duggal, Vladimír Džavík, Mark B Effron, Heather F Eng, Jorge Escobedo, Lise J Estcourt, Brendan M Everett, Dean A Fergusson, Mark Fitzgerald, Robert A Fowler, Joshua D Froess, Zhuxuan Fu, Jean P Galanaud, Benjamin T Galen, Sheetal Gandotra, Timothy D Girard, Andrew L Goodman, Herman Goossens, Cameron Green, Yonatan Y Greenstein, Peter L Gross, Rashan Haniffa, Sheila M Hegde, Carolyn M Hendrickson, Alisa M Higgins, Alexander A Hindenburg, Aluko A Hope, James M Horowitz, Christopher M Horvat, David T Huang, Kristin Hudock, Beverley J Hunt, Mansoor Husain, Robert C Hyzy, Jeffrey R Jacobson, Devachandran Jayakumar, Norma M Keller, Akram Khan, Yuri Kim, Andrei Kindzelski, Andrew J King, M Margaret Knudson, Aaron E Kornblith, Matthew E Kutcher, Michael A Laffan, Francois Lamontagne, Grégoire Le Gal, Christine M Leeper, Eric S Leifer, George Lim, Felipe Gallego Lima, Kelsey Linstrum, Edward Litton, Jose Lopez-Sendon, Sylvain A Lother, Nicole Marten, Andréa Saud Marinez, Mary Martinez, Eduardo Mateos Garcia, Stavroula Mavromichalis, Daniel F McAuley, Emily G McDonald, Anna McGlothlin, Shay P McGuinness, Saskia Middeldorp, Stephanie K Montgomery, Paul R Mouncey, Srinivas Murthy, Girish B Nair, Rahul Nair, Alistair D Nichol, Jose C Nicolau, Brenda Nunez-Garcia, John J Park, Pauline K Park, Rachael L Parke, Jane C Parker, Sam Parnia, Jonathan D Paul, Mauricio Pompilio, John G Quigley, Robert S Rosenson, Natalia S Rost, Kathryn Rowan, Fernanda O Santos, Marlene Santos, Mayler O Santos, Lewis Satterwhite, Christina T Saunders, Jake Schreiber, Roger E G Schutgens, Christopher W Seymour, Deborah M Siegal, Delcio G Silva Jr, Aneesh B Singhal, Arthur S Slutsky, Dayna Solvason, Simon J Stanworth, Anne M Turner, Wilma van Bentum-Puijk, Frank L van de Veerdonk, Sean van Diepen, Gloria Vazquez-Grande, Lana Wahid, Vanessa Wareham, R Jay Widmer, Jennifer G Wilson, Eugene Yuriditsky, Yongqi Zhong, Scott M Berry, Colin J McArthur, Matthew D Neal, Judith S Hochman, Steven A Webb, Ryan Zarychanski
Abstract
Background: Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.
Methods: In an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge.
Results: The trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio <1.2], 99.9%). The percentage of patients who survived to hospital discharge was similar in the two groups (62.7% and 64.5%, respectively; adjusted odds ratio, 0.84; 95% credible interval, 0.64 to 1.11). Major bleeding occurred in 3.8% of the patients assigned to therapeutic-dose anticoagulation and in 2.3% of those assigned to usual-care pharmacologic thromboprophylaxis.
Conclusions: In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis. (REMAP-CAP, ACTIV-4a, and ATTACC ClinicalTrials.gov numbers, NCT02735707, NCT04505774, NCT04359277, and NCT04372589.).
Copyright © 2021 Massachusetts Medical Society.
Figures
References
- Klok FA, Kruip MJHA, van der Meer NJM, et al.Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020;191:148-150.
- Middeldorp S, Coppens M, van Haaps TF, et al.Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020;18:1995-2002.
- Smilowitz NR, Kunichoff D, Garshick M, et al.C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J 2021;42:2270-2279.
- Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost 2020September25(Epub ahead of print).
- Poissy J, Goutay J, Caplan M, et al.Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 2020;142:184-186.
- Helms J, Tacquard C, Severac F, et al.High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46:1089-1098.
- Godoy LC, Goligher EC, Lawler PR, Slutsky AS, Zarychanski R. Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19. CMAJ 2020;192(40):E1156-E1161.
- Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA 2020;324:799-801.
- Zhou F, Yu T, Du R, et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-1062.
- Al-Samkari H, Karp Leaf RS, Dzik WH, et al.COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020;136:489-500.
- Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: do heparins have direct anti-inflammatory effects? Thromb Haemost 2017;117:437-444.
- Hippensteel JA, LaRiviere WB, Colbert JF, Langouët-Astrié CJ, Schmidt EP. Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol 2020;319:L211-L217.
- National Institute for Health and Care Excellence. (2020). COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19. NICE guideline 186. November20, 2020. ().
- Nadkarni GN, Lala A, Bagiella E, et al.Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 2020;76:1815-1826.
- Angus DC, Berry S, Lewis RJ, et al.The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) study: rationale and design. Ann Am Thorac Soc 2020;17:879-891.
- Houston BL, Lawler PR, Goligher EC, et al.Anti-thrombotic therapy to ameliorate complications of COVID-19 (ATTACC): study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clin Trials 2020;17:491-500.
- ATTACC, ACTIV-4a, and REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2105911.
- Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-694.
- McGlothlin AE, Viele K. Bayesian hierarchical models. JAMA 2018;320:2365-2366.
- Wijaya I, Andhika R, Huang I. The use of therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19: a systematic review. Clin Appl Thromb Hemost 2020;26:1076029620960797-1076029620960797.
- Ionescu F, Jaiyesimi I, Petrescu I, et al.Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis. Eur J Haematol 2021;106:165-174.
- Tritschler T, Mathieu M-E, Skeith L, et al.Anticoagulant interventions in hospitalized patients with COVID-19: a scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost 2020;18:2958-2967.
- Libster R, Pérez Marc G, Wappner D, et al.Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med 2021;384:610-618.
- Salama C, Han J, Yau L, et al.Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021;384:20-30.
- The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693-704.
- Wichmann D, Sperhake J-P, Lütgehetmann M, et al.Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020;173:268-277.
- Sadeghipour P, Talasaz AH, Rashidi F, et al.Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA 2021;325:1620-1630.
Source: PubMed